Efficacy and safety of pioglitazone, empagliflozin and glimepiride as third‐line agents in patients with type 2 diabetes inadequately controlled with metformin and <scp>DPP</scp> ‐4 inhibitors: A multicentre, phase 4 randomized controlled trial
The addition of empagliflozin, pioglitazone, or glimepiride to metformin and DPP-4 inhibitors significantly improved glycaemic control in patients with T2D. The selection of a third agent should be individualized based on the patient characteristics.
Authors
- Byung‐Wan Lee (ORCID: https://orcid.org/0000-0002-9899-4992)
- Kee‐Ho Song (ORCID: https://orcid.org/0000-0001-9276-6860)
- Sangmo Hong (ORCID: https://orcid.org/0000-0002-8535-0565)
- You‐Cheol Hwang (ORCID: https://orcid.org/0000-0003-4033-7874)
- Yun Kyung Cho (ORCID: https://orcid.org/0000-0002-4089-1376)
- Jee Hee Yoo (ORCID: https://orcid.org/0000-0002-2536-6274)
- Jae Hyeon Kim (ORCID: https://orcid.org/0000-0001-5001-963X)
- Jung Hwan Park (ORCID: https://orcid.org/0000-0002-8737-0084)
- Jae‐Hyoung Cho (ORCID: https://orcid.org/0000-0003-2235-8874)
- Sung Wan Chun (ORCID: https://orcid.org/0000-0001-7630-5204)
- Woo Je Lee (ORCID: https://orcid.org/0000-0002-1899-3560)
Institutions
- Ulsan College (KR)
- Konkuk University (KR)
- Soonchunhyang University (KR)
- Severance Hospital (KR)
- Asan Medical Center (KR)
- Samsung Medical Center (KR)
- University of Ulsan (KR)
- Konkuk University Medical Center (KR)
- St. Mary's Hospital (US)
- Hanyang University Guri Hospital (KR)
- Gangnam Severance Hospital (KR)
- Kyung Hee University Hospital at Gangdong (KR)
- Chung-Ang University Hospital (KR)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Hanyang University (KR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-08-14
- DOI
- https://doi.org/10.1111/dom.70030
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00